Natália Maria Maciel Guerra-Silva1, Fernanda Sene Santucci2, Ricardo Castanho Moreira2, Cristiano Massao Tashima2, Simone Cristina Castanho Sabaini de Melo2, Leonardo Regis Leira Pereira3, Debora de Mello Gonçales Sant'Ana4. 1. Graduate Program in Bioscience and Pathophysiology of the State University of Maringa, Maringa, Parana, Brazil.; Life Sciences Center nursing course at the State University of Northern Paraná, Campus Luiz Meneghel, Bandeirantes, Paraná, Brazil. Electronic address: natyguerra@uenp.edu.br. 2. Life Sciences Center nursing course at the State University of Northern Paraná, Campus Luiz Meneghel, Bandeirantes, Paraná, Brazil. 3. Faculty of Pharmaceutical Sciences, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. 4. Graduate Program in Bioscience and Pathophysiology of the State University of Maringa, Maringa, Parana, Brazil.
Abstract
INTRODUCTION: This study evaluated the risk of men developing coronary heart disease and its determinant variables, comparing these results through two validated coronary risk scales. METHODS: A cross sectional epidemiological analytical study in which data were collected by spontaneous demand, through a semi-structured questionnaire, clinical examination, and blood collection. The Chi-square test, logistic regression and Kappa for statistical analysis were performed. RESULTS: The study included 637 men. Age was a determining factor (p<0.05) in blood pressure (BP) changes, central obesity, BMI, glycemia, total cholesterol, LDL and triglycerides. From this group of 637, 252 presented BP above the recommended values. It was found that 34.54% of men had high total cholesterol, 19.94% had high LDL, 46.78% presented HDL below normal values and 36.42% had elevated triglycerides. Metabolic syndrome was found in 24.96% of the men. With the Framingham scale, 637 men were evaluated, 12.56% were at intermediate-risk and 5.49% elevated risk, while on the ASCVD Risk scale 553 men were evaluated, and 7.05% had moderate risk and none had high coronary risk. In this study, 50.43% of men still had no previous diagnosis for any disease that increases the risk factors. CONCLUSIONS: The determinant clinical variables were age, blood pressure, smoking, central obesity, race and education. The Framingham scale allowed the assessment of cardiac risk of all men in the study, with no age restriction or cholesterol value, so in population studies it shows advantages over the ASCVD Risk due to its comprehensive feature of including all individuals.
INTRODUCTION: This study evaluated the risk of men developing coronary heart disease and its determinant variables, comparing these results through two validated coronary risk scales. METHODS: A cross sectional epidemiological analytical study in which data were collected by spontaneous demand, through a semi-structured questionnaire, clinical examination, and blood collection. The Chi-square test, logistic regression and Kappa for statistical analysis were performed. RESULTS: The study included 637 men. Age was a determining factor (p<0.05) in blood pressure (BP) changes, central obesity, BMI, glycemia, total cholesterol, LDL and triglycerides. From this group of 637, 252 presented BP above the recommended values. It was found that 34.54% of men had high total cholesterol, 19.94% had high LDL, 46.78% presented HDL below normal values and 36.42% had elevated triglycerides. Metabolic syndrome was found in 24.96% of the men. With the Framingham scale, 637 men were evaluated, 12.56% were at intermediate-risk and 5.49% elevated risk, while on the ASCVD Risk scale 553 men were evaluated, and 7.05% had moderate risk and none had high coronary risk. In this study, 50.43% of men still had no previous diagnosis for any disease that increases the risk factors. CONCLUSIONS: The determinant clinical variables were age, blood pressure, smoking, central obesity, race and education. The Framingham scale allowed the assessment of cardiac risk of all men in the study, with no age restriction or cholesterol value, so in population studies it shows advantages over the ASCVD Risk due to its comprehensive feature of including all individuals.
Authors: Mahmoud M A Abulmeaty; Ali M Almajwal; Najwa K Almadani; Mona S Aldosari; Ahmed A Alnajim; Saeed B Ali; Heba M Hassan; Hany A Elkatawy Journal: Saudi Med J Date: 2017-04 Impact factor: 1.484
Authors: Lily D Yan; Jean Lookens Pierre; Vanessa Rouzier; Michel Théard; Alexandra Apollon; Stephano St Preux; Justin R Kingery; Kenneth A Jamerson; Marie Deschamps; Jean W Pape; Monika M Safford; Margaret L McNairy Journal: BMC Public Health Date: 2022-03-19 Impact factor: 4.135
Authors: Mohamad Habes; Guray Erus; Jon B Toledo; Nick Bryan; Deborah Janowitz; Jimit Doshi; Henry Völzke; Ulf Schminke; Wolfgang Hoffmann; Hans J Grabe; David A Wolk; Christos Davatzikos Journal: Alzheimers Dement (Amst) Date: 2018-03-05